Intensity-fading MALDI-TOF-MS: novel screening for ligand binding and drug discovery

Abstract Ligand discovery technologies largely rely on a primary screening for molecules showing affinity to a target, coupled with an approach to identify these molecules. Matrix-assisted laser desorption ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS) is attracting increasing attention as a suitable analytical technique for ligand identification owing to its high sensitivity and capacity for discrimination, its fast analysis and its ease of automation. There is now a range of related strategies for drug discovery, including a novel MS-based methodology to screen noncovalent interactions between macromolecular targets (proteases) and peptide or organic ligands (protease inhibitors) called intensity-fading (IF) MALDI-TOF-MS.

[1]  M. Mann,et al.  Analysis of proteins and proteomes by mass spectrometry. , 2001, Annual review of biochemistry.

[2]  R. Knochenmuss,et al.  Secondary ion-molecule reactions in matrix-assisted laser desorption/ionization , 2000, Journal of mass spectrometry : JMS.

[3]  Enrique Querol,et al.  Ligand screening by exoproteolysis and mass spectrometry in combination with computer modelling. , 2003, Journal of molecular biology.

[4]  E. Querol,et al.  Monitoring the expression and purification of recombinant proteins by MALDI-TOF mass spectrometry. , 2001, Enzyme and microbial technology.

[5]  R Zenobi,et al.  MALDI ionization: the role of in-plume processes. , 2003, Chemical reviews.

[6]  P. Rosner,et al.  Strategic use of affinity-based mass spectrometry techniques in the drug discovery process. , 2002, Analytical chemistry.

[7]  Richard M Caprioli,et al.  Direct profiling and imaging of peptides and proteins from mammalian cells and tissue sections by mass spectrometry , 2002, Electrophoresis.

[8]  Mark W. Duncan,et al.  Practical quantitative biomedical applications of MALDI-TOF mass spectrometry , 2002, Journal of the American Society for Mass Spectrometry.

[9]  Enrique Querol,et al.  Identification of protein ligands in complex biological samples using intensity-fading MALDI-TOF mass spectrometry. , 2003, Analytical chemistry.

[10]  C. Southan,et al.  A genomic perspective on human proteases as drug targets. , 2001, Drug discovery today.

[11]  P. Vouros,et al.  Mass spectrometric identification of ligands selected from combinatorial libraries using gel filtration , 1997 .

[12]  Lenz,et al.  Chemical ligands, genomics and drug discovery. , 2000, Drug discovery today.

[13]  T. Annesley Ion suppression in mass spectrometry. , 2003, Clinical chemistry.

[14]  Gary Walsh,et al.  Biopharmaceuticals: Biochemistry and Biotechnology , 1998 .

[15]  Z. Weng,et al.  Protein therapeutics: promises and challenges for the 21st century. , 2002, Trends in biotechnology.

[16]  J. Drews Drug discovery: a historical perspective. , 2000, Science.

[17]  P. Ashton,et al.  Linking proteome and genome: how to identify parasite proteins. , 2001, Trends in parasitology.